FY2024 EPS Forecast for Hoth Therapeutics Reduced by Analyst

Hoth Therapeutics, Inc. (NASDAQ:HOTH) – Equities research analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Hoth Therapeutics in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($1.36) for the year, down from their previous forecast of ($1.18). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Hoth Therapeutics’ current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Hoth Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.18) EPS and FY2025 earnings at ($0.97) EPS.

A number of other equities analysts have also issued reports on the stock. Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of Hoth Therapeutics in a research report on Friday, October 11th. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price objective on shares of Hoth Therapeutics in a report on Tuesday, January 7th.

Hoth Therapeutics Stock Performance

NASDAQ:HOTH opened at $1.29 on Monday. The stock has a market cap of $8.90 million, a price-to-earnings ratio of -0.98 and a beta of 0.75. Hoth Therapeutics has a 1 year low of $0.58 and a 1 year high of $3.80. The business has a fifty day moving average of $1.06 and a 200-day moving average of $0.92.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.01).

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics as of its most recent filing with the Securities and Exchange Commission. 7.08% of the stock is owned by institutional investors and hedge funds.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.